NCT03207451 - Vorapaxar on Thrombin Generation and Coagulability | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

July 1, 2018

Study Completion Date

August 1, 2018

Conditions

Coronary Artery DiseasePeripheral Vascular DiseaseMyocardial Infarction

Interventions

DRUG

Vorapaxar

Vorapaxar is the principle study drug and will be given to all subjects.

DRUG

Vorapaxar and Aspirin

Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.

DRUG

Vorapaxar and Clopidogrel

Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.

DRUG

Vorapaxar, Aspirin, and Clopidogrel

Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.

Trial Locations (1)

Inova Fairfax Hospital, Falls Church